recombinant human vitronectin (MedChemExpress)
Structured Review

Recombinant Human Vitronectin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human vitronectin/product/MedChemExpress
Average 94 stars, based on 12 article reviews
Images
1) Product Images from "The Role of CAF‐derived Vitronectin in Promoting Colorectal Cancer Progression and Immunosuppression"
Article Title: The Role of CAF‐derived Vitronectin in Promoting Colorectal Cancer Progression and Immunosuppression
Journal: Advanced Science
doi: 10.1002/advs.202505769
Figure Legend Snippet: Vitronectin Significantly Up‐regulated in CAFs Correlates with Poor Clinical Outcomes in CRC Patients A) Venn diagram demonstrating the intersection of upregulated differentially expressed genes (DEGs) in cancer‐associated fibroblasts (CAFs) compared to normal fibroblasts (NFs), as identified in GSE51257 , GSE92945 , and GSE231559 datasets. B) Heatmap showing the expression patterns of the overlapping genes across the three datasets. C) Violin plots illustrating the expression levels of fibroblast marker genes (ACTA2, COL1A1, COL1A2) and VTN within each cluster, based on a single‐cell RNA sequencing dataset ( GSE231559 ) comprising 6 CRC tissues and 3 adjacent normal tissues. D) tSNE plot of total fibroblasts isolated and re‐clustered from GSE231559 , color‐coded by sample origin (left) and VTN expression (right). E) Representative images of immunofluorescence costaining for VTN (red) with cell‐type markers (green) in CRC tissues from patients. Scale bars: 50 µm. F) Representative images of immunofluorescence co‐staining for VTN (red) with Vimentin, S100A4, and FAP (green) in CRC tissues from patients. Scale bars: 100 µm. G) Representative immunohistochemical staining of VTN in CRC tissue microarray. Magnification: 10X (left) and 200X (right). P: Parenchyma; S: Stroma. H) Immunohistochemical Scoring of VTN in CRC tissues and adjacent normal tissues. Student's t‐test. ***p<0.001. I) Classification of CRC and adjacent tissues into high and low VTN expression groups, followed by Chi‐Square test analysis. p<0.0001, χ2 = 26.97. J) Kaplan‐Meier survival analysis of the impact of VTN expression intensity on progression‐free survival (PFS, left) and overall survival (OS, right) of CRC patients. n = 33 patients for VTN‐low group; n = 47 patients for VTN‐high group. Log‐rank test. p<0.001. K) Higher VTN expression is associated with poorer PFS in The Cancer Genome Atlas (TCGA) CRC cohort (left), and increased distant metastasis rates in the GSE72970 CRC cohort (right). L,M) Verification of CAFs and NFs isolated from CRC tissues and paired noncancerous tissues by immunofluorescent staining (L) and western blot (M) for α‐SMA, Vimentin, FAP, and VTN, with higher expression observed in CAFs compared to NFs. Scale bar: 100 µm. N) qRT‐PCR analysis of VTN mRNA levels in 34 pairs of NFs and CAFs isolated from CRC patients. Paired two‐tailed Student's t‐test was used to calculate p value. P) ELISA detection of VTN expression in plasma samples from CRC patients (n = 36) and healthy individuals (n = 35). Student's t‐test was used to calculate p value. CAFs, cancer‐associated fibroblasts; NF, normal fibroblasts; t‐SNE, t‐distributed stochastic neighbor embedding; CRC, colorectal cancer.
Techniques Used: Expressing, Marker, RNA Sequencing, Isolation, Immunofluorescence, Staining, Immunohistochemical staining, Microarray, Western Blot, Quantitative RT-PCR, Two Tailed Test, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

